Search Results for "Contraceptives"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Contraceptives. Results 61 to 70 of 257 total matches.
Osimertinib (Tagrisso) for Adjuvant Treatment of NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023 (Issue 1682)
use effective
contraception during treatment and for 6 weeks
after the last dose and males ...
The FDA has approved osimertinib (Tagrisso –
AstraZeneca), an oral kinase inhibitor, for adjuvant
treatment of non-small cell lung cancer (NSCLC)
after tumor resection in adults who have epidermal
growth factor receptor (EGFR) exon 19 deletions or
exon 21 L858R mutations. Osimertinib is the first
targeted therapy to be approved in the US for this
indication. The drug was previously approved for
first-line treatment of adults with NSCLC with EGFR
exon 19 deletions or exon 21 L858R mutations and for
treatment of EGFR T790M mutation-positive NSCLC
in adults whose disease progressed...
Med Lett Drugs Ther. 2023 Aug 7;65(1682):e131-2 doi:10.58347/tml.2023.1682c | Show Introduction Hide Introduction
Rifapentine--A Long-Acting Rifamycin for Tuberculosis
The Medical Letter on Drugs and Therapeutics • Feb 26, 1999 (Issue 1047)
(Crixivan), and probably those of other protease inhibitors, oral contraceptives and many other drugs ...
Rifapentine, a long-acting analog of rifampin developed in the 1960's, has received an accelerated approval from the FDA for oral use, with at least one other drug, in the treatment of pulmonary tuberculosis.
Neratinib (Nerlynx) for Metastatic HER2-Positive Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
should use effective
contraception during neratinib treatment and for at
least one month after the last ...
The oral tyrosine kinase inhibitor neratinib (Nerlynx –
Puma Biotechnology) has been approved by the FDA
for use in combination with capecitabine (Xeloda, and
generics) for treatment of advanced or metastatic
human epidermal growth factor receptor 2 (HER2)-positive breast cancer in adults who received ≥2 prior
anti-HER2-based regimens for metastatic disease.
It was previously approved for use as monotherapy
for extended adjuvant treatment of adults with early-stage,
HER2-positive breast cancer following adjuvant
trastuzumab (Herceptin)-based therapy. HER2 is
overexpressed in...
In Brief: OTC Ivermectin for Head Lice
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023 (Issue 1679)
. Medication abortion with misoprostolonly:
a sample protocol. Contraception 2023; 121:109998.
3. R ...
Topical ivermectin lotion 0.5% (Sklice, and generics),
which has been available by prescription since 2012,
is now FDA-approved for sale over the counter (OTC)
for treatment of head lice in patients ≥6 months old.
Ivermectin is also available by prescription as a 1%
cream (Soolantra) approved for topical treatment of
inflammatory lesions of rosacea and in oral tablets
(Stromectol, and generics) for treatment of various
parasitic infections.
Med Lett Drugs Ther. 2023 Jun 26;65(1679):103-4 doi:10.58347/tml.2023.1679e | Show Introduction Hide Introduction
Tizanidine for Spasticity
The Medical Letter on Drugs and Therapeutics • Jul 04, 1997 (Issue 1004)
of tizanidine. Oral contraceptives decrease the clearance of tizanidine by 50%; the starting
dosage ...
Tizanidine (Zanaflex - Athena Neurosciences) has been approved by the US Food and Drug Administration for oral treatment of increased muscle tone associated with spasticity. It has been available in Europe and Japan for 12 years as a short-term muscle relaxant.
Encorafenib (Braftovi) for Metastatic Colorectal Cancer
The Medical Letter on Drugs and Therapeutics • Jan 25, 2021 (Issue 1616)
contraceptives. It should not be coadministered with
other drugs that also prolong the QT interval.4
Table 1 ...
The FDA has approved the oral kinase inhibitor
encorafenib (Braftovi – Pfizer), in combination with
the epidermal growth factor receptor (EGFR) inhibitor
cetuximab (Erbitux), for treatment of adults with
metastatic colorectal cancer (CRC) with a BRAF
V600E mutation. Encorafenib was approved in 2018
for use with the mitogen-activated kinase (MEK)
inhibitor binimetinib (Mektovi) for treatment of
unresectable or metastatic melanoma with a BRAF
V600E or V600K mutation.
In Brief: Dabrafenib (Tafinlar) and Trametinib (Mekinist) for Glioma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
concentrations of many
drugs, including midazolam, warfarin, dexamethasone,
and hormonal contraceptives ...
The oral kinase inhibitors dabrafenib (Tafinlar –
GSK) and trametinib (Mekinist – Novartis) have been
approved by the FDA for use together for a sixth
indication: treatment of low-grade glioma (LGG)
with a BRAF V600E mutation in patients ≥1 years old
who require systemic therapy. This combination is
the first systemic therapy to be approved in the US
for first-line treatment of LGG with a BRAF V600E
mutation in pediatric patients. The FDA also approved
new oral formulations of both drugs for patients
who are unable to swallow dabrafenib capsules or
trametinib...
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e75-6 doi:10.58347/tml.2023.1674i | Show Introduction Hide Introduction
Angeliq for Treatment of Menopausal Symptoms
The Medical Letter on Drugs and Therapeutics • Feb 12, 2007 (Issue 1254)
properties. Drospirenone is also
available in the combination oral contraceptives Ya z
and Yasmin.
1 ...
A combination tablet containing estradiol and drospirenone (Angeliq - Berlex) recently became available for treatment of moderate to severe menopausal symptoms in women with an intact uterus. Since the last Medical Letter issue reviewing such devices,1 more continuous glucose monitoring (CGM) systems have become available. Five devices available now, and two expected to be marketed soon, are listed in the table on page 14. The FDA has approved continuous glucose devices only for the observation of glucose trends.
Preservation of Ovarian Function During Chemotherapy
The Medical Letter on Drugs and Therapeutics • Jun 28, 2010 (Issue 1341)
small observational studies suggest that oral contraceptive pills
may preserve ovarian function,
6,7 ...
Chemotherapy can result in premature menopause and infertility in young women. Pretreatment fertility
counseling followed by appropriate action may prevent some of these undesirable consequences.
Brigatinib (Alunbrig) for Non-Small Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Apr 23, 2018 (Issue 1545)
23, 2018
serum concentrations of other CYP3A substrates,
including oral contraceptives.7
PREGNANCY ...
The FDA has approved brigatinib (Alunbrig – Takeda),
an oral tyrosine kinase inhibitor, for treatment of
patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)
who have progressed on or are intolerant to crizotinib
(Xalkori). Translocations of the ALK gene are found in
about 5% of lung cancers; they occur predominantly
in nonsmokers with adenocarcinoma. Brigatinib is the
third tyrosine kinase inhibitor to be approved for this
indication; ceritinib (Zykadia) and alectinib (Alecensa)
were approved earlier, and subsequently were...